Navigation Links
GeneLink Marketing Efforts Poised to Show Results

ORLANDO, Fla., Nov. 21, 2011 /PRNewswire/ -- GeneLink, Inc. (OTCBB: GNLK.OB, "the Company," or "GeneLink"), a leading consumer genomics biotech company, reported financial results for the quarter ended September 30th, 2011.

Bernard L. Kasten, M.D., GeneLink's Chairman and CEO stated, "From a business development potential, the third quarter has been the most exciting period in the history of the Company.  The Company continues to make progress towards the launch of two exciting new personalized consumer product lines.  These include a large scale direct-to-consumer initiative featuring a new brand being launched with Robert B. Trussell, Jr., Founder and Vice-Chairman of Tempur-Pedic, Inc.  In addition to this opportunity, in early 2012 we will launch a specialized exclusive product line for aesthetic physicians under GeneLink's Dermagenetics® brand.  We have already developed a unique line of products and are working with world class marketing partners for our initial launch into this arena."

Dr. Kasten added, "Importantly, the third quarter was most notable for our announced pending sale of GeneWize, our direct selling subsidiary, to Capsalus Corp. (OTCBB: WELL).  The definitive agreements which we executed on October 13, 2011 provide us with a motivated and experienced marketing partner in multiple direct selling channels.  Once we receive the necessary GeneLink's shareholder approval for the sale of GeneWize to Capsalus, we will be especially pleased to have positioned GeneWize and its marketing affiliates for success." 

Financial Results for the three months ended September 30, 2011 , are comprised mainly of sales from the Company's GeneWize direct selling subsidiary, and  compared to 2010 results as follows:

  • Net sales were $1,069,760, compared to $1,877,136 in the prior year.
  • Gross profit margins decreased to 59%, compared to 66.8% in the prior year.
  • Operating losses were $880,009 compared to $822,970 in the prior year.  

John A. Webb, GeneLink's, CFO added:  "Financially, the pending sale of GeneWize has provided an attractive way to expand our operating infrastructure in support of our distribution partners.  In each relationship, our partners will be selling services and products purchased from GeneLink.  This business model is designed to allow GeneLink to sell more products, at stronger margins, with reduced overhead. It also allows management and our renowned Scientific Advisory Board to extend GeneLink's position as a consumer genomics leader through focused efforts in developing new and innovative assessments, products, and customization methodologies."

Dr. Kasten concluded, "The short term future of GeneLink is more promising than at any time in the history of this Company.  We at GeneLink intend to remain a leader in the burgeoning field of personalized consumer genetics for years to come."

About GeneLink Biosciences, Inc.:

GeneLink is a 17-year old leading biosciences company specializing in consumer genomics. GeneLink's patented technologies include proprietary DNA assessments linked to personalized nutrition, skincare and wellness applications and products.  For more information visit

This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.




SOURCE GeneLink, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GeneLink BioSciences, Inc. Ranked Number 33 Fastest Growing Company in North America on Deloittes 2011 Technology Fast 500™
2. GeneLink Reports Second Quarter 2011 Results
3. GeneLink Biosciences Expands its Scientific Advisory Board to Support New Product Lines
4. GeneLink Reports Denial of Appeal
5. GeneLink Reports 2010 Results
6. GeneLink Announces New Licensing Partner
7. GeneLink Reports Third Quarter Results
8. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
9. GeneLink Announces HelixLife Private Label Distribution Agreement
10. GeneLink Reports First Quarter Gains
11. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
Post Your Comments:
(Date:11/24/2015)... , ... November 24, 2015 , ... ... of the year and one of the premier annual events for pharmaceutical manufacturing: ... from 8–11 November 2015, where ISPE hosted the largest number of attendees in ...
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
(Date:11/24/2015)... 24, 2015 SHPG ) announced today that ... Piper Jaffray 27 th Annual Healthcare Conference in ... at 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ ... (the "Company") announced today that the remaining 11,000 ... Common Share Purchase Warrants (the "Series B Warrants") ... agreement were exercised on November 23, 2015, which ... Common Shares.  After giving effect to the issuance ...
Breaking Biology Technology:
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):